Powder: -20°C for 3 years | In solvent: -80°C for 1 year
TL02-59 is a selective inhibitor of Fgr in Src-family kinase (IC50 = 0.03 nM). TL02-59 inhibits Lyn and Hck with IC50s of 0.1 nM and 160 nM, respectively. TL02-59 potently suppresses acute myelogenous leukemia cell growth.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 108.00 | |
5 mg | In stock | $ 228.00 | |
10 mg | In stock | $ 372.00 | |
25 mg | In stock | $ 629.00 | |
50 mg | In stock | $ 896.00 | |
100 mg | In stock | $ 1,220.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 297.00 |
Description | TL02-59 is a selective inhibitor of Fgr in Src-family kinase (IC50 = 0.03 nM). TL02-59 inhibits Lyn and Hck with IC50s of 0.1 nM and 160 nM, respectively. TL02-59 potently suppresses acute myelogenous leukemia cell growth. |
Targets&IC50 | FGR:0.03 nM , Hck:160 nM , Lyn:0.1 nM |
In vitro | TL02-59 inhibits the growth and induced apoptosis of AML cell lines expressing this kinase with single-digit nM potency. TL02-59 induces growth arrest in primary AML bone marrow samples. In TF-1 myeloid cells, TL02-59 (0.1, 1, 10, 100, 1000 nM; 6 h) potently inhibits Fgr autophosphorylation in TF-1 cells, with paritial inhibition at 0.1-1 nM and complete inhibition above 10 nM. Hck, Lyn and Flt3 are inhibited in the 100 to 1000 nM range[1]. |
In vivo | In mice, TL02-59 (1, 10 mg/kg; oral) completely eliminates AML cells from the spleen and peripheral blood while dramatically suppressing bone marrow involvement. TL02-59 has a t1/2 of 5.7 h by i.v and 6.5 h by p.o., respectively[1]. |
Molecular Weight | 609.64 |
Formula | C32H34F3N5O4 |
CAS No. | 1315330-17-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 120 mg/mL (196.84 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
TL02-59 1315330-17-6 Angiogenesis Apoptosis Tyrosine Kinase/Adaptors Src Hck TL-02-59 Inhibitor Lyn leukemia inhibit acute orally AML TL02 59 TL0259 myelogenous Fgr inhibitor